Namir Hassan has been named chief scientific officer of Zelluna Immunotherapy, a privately-held Norwegian biotech specializing in T-cell receptor (TCR) immunotherapies.
Dr Hassan joins from UK-based Immunocore, where he was praised for building and growing the biology, preclinical and biomarker units targeting oncology, and oversaw early development and the first-in-human trial of a TCR based biologic targeting a melanoma antigen, gp100. He has also worked at pharma major GlaxoSmithKline (LSE: GSK) and at the Ludwig Institute for Cancer Research.
"I joined Zelluna because I believe these TCRs provide opportunities for driving differentiated therapeutic benefits in patients fighting solid cancers"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze